Login| Sign Up| Help| Contact|

Patent Searching and Data


Matches 501 - 550 out of 106,113

Document Document Title
WO/2015/021904A1
Disclosed is a method for synthesizing glatiramer acetate. The present method uses two or multiple depolymerization steps to control the average molecular weight of the glatiramer acetate product within a relatively narrow range.  
WO/2015/023890A1
A glycosylated pleiotropic peptide pituitary adenylate cyclase-activating polypeptide (PACAP) which can both agonize PAC, receptors, causing neuroprotective effects, and antagonize VPAC receptors, causing anti-inflammation in several mod...  
WO/2015/023871A1
Alcoholism, and symptoms and negative effects thereof may be treated using ibudilast or a pharmaceutically acceptable salt thereof. Abstinence from alcohol consumption may be maintained using ibudilast or a pharmaceutically acceptable sa...  
WO/2015/022418A1
This invention relates to the treatment of varying degrees of cognitive impairment associated with, for example, aging, Alzheimer's disease, schizophrenia with low dose administration of a PDE4 inhibitor, specifically roflumilast.  
WO/2015/023593A1
This disclosure relates to progesterone phophate derivatives and uses related thereto. In certain embodiments, the disclosure relates to compounds disclosed herein and uses for managing inflammation such as those resulting from traumatic...  
WO/2015/022831A1
[Problem] To provide: a composition for promoting estrogen secretion and that is able to promote estrogen secretion; an estrogen secretion aromatic composition; and an estrogen aromatic tool. [Solution] The composition that is for promot...  
WO/2015/022417A1
Treatment of varying degrees of cognitive impairment associated with Alzheimer's disease with a combination of a phosphodiesterase 4 inhibitor and an acetylcholinesterase inhibitor, including roflumilast and donepezil hydrochloride.  
WO/2015/023244A9
The invention relates to medicine and to the chemical and pharmaceutical industry, in particular for creating, producing and using cerebro-protective agents for treating and improving blood circulation in the brain. The drug comprises 12...  
WO/2015/020565A1
This invention relates to novel compounds - substituted [1,2,4]-triazolo[4,3-а]pyridines of general formula (I), or the pharmaceutically acceptable salts thereof, where A is an unsubstituted or substituted aminocarbonyl group -N-С(...  
WO/2015/020241A1
The present invention relates to a composition containing a Galla rhois extract as an active ingredient for improving cognition, and more specifically, to a composition containing a Galla rhois extract as an active ingredient, for preven...  
WO/2015/021191A1
In accordance with the present invention, there are provided formulations of gamma secretase modulators (GSMs) which are suitable for oral delivery and have improved transport properties relative to prior art formulations thereof. Also p...  
WO/2015/020234A1
The present invention provides a method for more efficiently producing high-quality dopaminergic neurons from neuron precursor cells. More specifically, the present invention provides a method for producing dopaminergic neurons, which is...  
WO/2015/018375A1
Provided in the present invention are a depression regulatory factor and applications thereof. Specifically, provided in the present invention are applications of βCaMKII inhibitor in preparation of a medicament for prevention and/or tr...  
WO/2015/021187A1
Provided are mutant cocaine esterase polypeptides and PEGylated formulations thereof.  
WO/2015/018029A1
The present invention is directed to oxazole compounds which are antagonists of orexin receptors. The present invention is also directed to uses of the oxazole compounds described herein in the potential treatment or prevention of neurol...  
WO/2015/019334A1
The present invention relates to pharmaceutical compositions having analgesic and/or anti- inflammatory effect comprising the combination of diosmin and hesperidin, and the use of said composition for the treatment of pain; e.g., moderat...  
WO/2015/018356A1
The present invention discloses a diarylhydantoin derivative, and preparation method, pharmaceutical composition, and application thereof. The present invention provides a diarylhydantoin derivative as represented by formula I, a pharmac...  
WO/2015/018827A1
The present invention is related to NDP-MSH or pharmaceutically acceptable salts thereof for therapeutic and/or prophylactic therapeutic treatment of inflammatory and/or neurodegenerative disorders of the CNSor multiple sclerosis. The pr...  
WO/2015/018475A1
Compounds of the formula I in which R1-R3 have the meanings indicated in Claim 1, are inhibitors of Tankyrase, and can be employed, inter alia, for the treatment of diseases such as cancer, cardiovascular diseases, central nervous system...  
WO/2015/020545A3
The invention discloses new derivatives of N-[(phenoxy)ethoxy]alkylaminoalkanols with the structure which show pharmacological activity, especially in therapy and/or prophylaxis disorders and/or symptoms withneurological etiology.  
WO/2015/017900A1
The present disclosure relates generally to a protocol to treat or prevent diseases or conditions associated with pathological forms of amyloid beta (Aβ), including Alzheimer's disease. Enabled herein is a reagent for use in the treatme...  
WO/2015/016392A1
The purpose of the present invention is to provide a method for detecting ALS. The present invention pertains to an ALS detection method characterized in that of the ERBB4 gene base sequence sampled from a subject, the genetic alteration...  
WO/2015/014768A1
The present invention relates to compounds of general formula (I) wherein R1 is phenyl or pyridinyl, which are optionally substituted by one, two or three substituents, selected from halogen, lower alkyl substituted by halogen, lower alk...  
WO/2015/016206A1
The present invention provides a prophylactic or therapeutic agent for autoimmune disease (e.g., psoriasis, rheumatoid arthritis, inflammatory bowel disease, Sjogren's syndrome, Behcet's disease, multiple sclerosis, systemic lupus erythe...  
WO/2015/013865A1
Disclosed are agomelatine sulfonic acids complexes having the specific stoichiometry of 2 molar equivalents of agomelatine for 1 molar equivalent of sulfonic acids. Those complexes show excellent solubility, stability and purity, making ...  
WO/2015/014838A1
The present invention relates to an inhibitor of neurocalcin delta (NCALD) for use in a method for the treatment or prevention of a patient suffering from a disorder associated with a pathological calcium homeostasis. Furthermore, the pr...  
WO/2015/016695A1
The present invention relates to stable pharmaceutical compositions comprising a tablet/tablet system, consisting of the compression of a tablet within another tablet with a biphasic-delivery system of at least one analogue of (1R, 2R)-2...  
WO/2015/017280A1
The present invention relates to compositions and methods for the prevention and treatment of neurodegenerative diseases, such Alzheimer's disease, that are caused by misfolding, aggregating proteins. The compositions and methods of the ...  
WO/2015/014816A1
The invention refers to compounds of general formula (I) wherein the variables take various meanings, pharmaceutical compositions containing them and their use in medicine, particularly in pain therapy.  
WO/2015/017412A1
The disclosure includes compounds and pharmaceutically acceptable salts of Formula (I). Certain compounds and salts of Formula (I) are selective inhibitors of the Dopamine D2 receptor. The variables R1-R4, n, and L are defined herein. Th...  
WO/2015/014256A1
Provided herein are novel heteroaryl compounds, pharmaceutically acceptable salts and pharmaceutical formulations thereof for selectively inhibiting serotonin reuptake and/or acting as 5-HT1A receptor agonists. Also provided herein are p...  
WO/2015/016285A1
Provided is a brain function-improving composition which can inhibit binding of homocysteic acid to a receptor (NMDA receptor) and, at the same time, decrease the binding ability of homocysteic acid per se to the receptor to thereby impr...  
WO/2015/015185A1
A method for producing an engineered tissue scaffold for neural repair is described. The method includes tethering a hydrogel matrix seeded with tension-generating cells to a frame, and allowing the tension-generating cells to generate t...  
WO/2015/014442A1
Compounds of the formula I in which R1-R3 and Z have the meanings indicated in Claim 1, are inhibitors of Tankyrase, and can be employed, inter alia, for the treatment of diseases such as cancer, cardiovascular diseases, central nervous ...  
WO/2015/017715A1
The present invention relates to a new drug delivery strategy based on prodrug conversion, in which a water-soluble prodrug and its converting enzyme are co-delivered and at a point of administration such as the nasal or buccal mucosa. E...  
WO/2015/017407A1
The present invention provides a new class of compounds useful for the modulation of beta-secretase enzyme (BACE) activity. The compounds have a general Formula I, wherein variables A4, A5, A6, A8, R1, R2, R3, R7and n of Formula I, indep...  
WO/2015/013903A1
The present invention relates to the p-toluenesulfonic acid co-crystals of agomelatine of formula (I), preparation and use thereof, and to pharmaceutical composition containing it. The p-toluenesulfonic acid co-crystals of agomelatine ob...  
WO/2015/014884A1
The invention relates to a fusion protein comprising an antibody directed to Aβ, a monovalent binding entity which binds to a blood brain barrier receptor and a neprilysin.  
WO/2015/016667A1
The present invention relates to an orally disintegrating film preparation containing donepezil, and a preparation method therefor and particularly, to an orally disintegrating film preparation for treating dementia, containing donepezil...  
WO/2015/017123A1
The present disclosure relates, in one aspect, to use of ghrelin splice variant or an analogue thereof, or a ghrelin splice variant-like compound for the preparation of a medicament for one or more of: treatment and/or prevention of neur...  
WO/2015/010210A1
Compounds of general formula (I) and their use to reduce circulating acylated ghrelin levels are provided. GSA-X-Y-B (I) in which "GSA-X" is a ghrelin moiety, "Y" is an optional peptide linker and "B" is a CPP moiety. The compounds of ge...  
WO/2015/011038A1
Compositions contain a therapeutically effective amount of tiglic aldehyde for at least one of provoking the swallowing reflex of dysphagic patients, decreasing appetite by delaying gastric emptying, reducing body weight gain, or reducin...  
WO/2015/010655A1
Triadic fused cyclic carboxylic acids derivatives, preparation method therefor and pharmaceutical use thereof, particularly relating to compounds represented by general formula (I), stereoisomers, hydrates, solvates, metabolites, eutecti...  
WO/2015/011037A1
Compositions contain a therapeutically effective amount of cuminaldehyde for at least one of provoking the swallowing reflex of dysphagic patients, decreasing appetite by delaying gastric emptying, reducing body weight gain, or reducing ...  
WO/2015/012708A1
A compound having a structure selected from the following: or a pharmaceutically acceptable salt thereof. The compound may be used as an inhibitor of fatty acid amide hydrolase.  
WO/2015/011036A1
Compositions contain a therapeutically effective amount of p-anisaldehyde for at least one of provoking the swallowing reflex of dysphagic patients, decreasing appetite by delaying gastric emptying, reducing body weight gain, or reducing...  
WO/2015/012704A1
This invention concerns pyrroloquinoline derivatives as antagonists of 5-HT6 receptors, to methods for the preparation of these compounds and to novel intermediates useful for their synthesis. The invention also relates to the uses of su...  
WO/2015/011189A1
The present invention is concerned with an oral pharmaceutical dosage form comprising oxycodone or a pharmaceutically acceptable salt thereof and naloxone or a pharmaceutically acceptable salt thereof for use in the treatment of pain in ...  
WO/2015/012328A1
A compound represented by formula (I) [In the formula, each symbol is as described in the specification.] or a salt thereof has a PDE2A inhibitory action and is effective as a preventive and therapeutic agent for schizophrenia, Alzheimer...  
WO/2015/012400A1
The present invention provides a novel compound represented by the following formula (I), or a pharmaceutically acceptable salt thereof, which, on the basis of glycine reuptake inhibiting action, is useful in prevention or treatment of d...  

Matches 501 - 550 out of 106,113